image
Healthcare - Medical - Devices - NASDAQ - US
$ 16.39
-1.74 %
$ 698 M
Market Cap
-26.02
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SIBN stock under the worst case scenario is HIDDEN Compared to the current market price of 16.4 USD, SI-BONE, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SIBN stock under the base case scenario is HIDDEN Compared to the current market price of 16.4 USD, SI-BONE, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SIBN stock under the best case scenario is HIDDEN Compared to the current market price of 16.4 USD, SI-BONE, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SIBN

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
167 M REVENUE
20.37%
-35.2 M OPERATING INCOME
24.89%
-30.9 M NET INCOME
28.67%
-12.4 M OPERATING CASH FLOW
33.60%
12.6 M INVESTING CASH FLOW
121.11%
1.96 M FINANCING CASH FLOW
-97.85%
47.3 M REVENUE
-3.49%
-7.48 M OPERATING INCOME
-36.15%
-6.54 M NET INCOME
-45.51%
-4.91 M OPERATING CASH FLOW
-416.89%
10.6 M INVESTING CASH FLOW
145.10%
103 K FINANCING CASH FLOW
232.05%
Balance Sheet SI-BONE, Inc.
image
Current Assets 208 M
Cash & Short-Term Investments 150 M
Receivables 27.5 M
Other Current Assets 30.3 M
Non-Current Assets 22.7 M
Long-Term Investments 0
PP&E 22.4 M
Other Non-Current Assets 300 K
65.11 %11.92 %13.14 %9.70 %Total Assets$230.4m
Current Liabilities 27.1 M
Accounts Payable 6.49 M
Short-Term Debt 1.15 M
Other Current Liabilities 19.5 M
Non-Current Liabilities 36.3 M
Long-Term Debt 36.3 M
Other Non-Current Liabilities 10 K
10.22 %30.71 %57.24 %Total Liabilities$63.5m
EFFICIENCY
Earnings Waterfall SI-BONE, Inc.
image
Revenue 167 M
Cost Of Revenue 35.1 M
Gross Profit 132 M
Operating Expenses 167 M
Operating Income -35.2 M
Other Expenses -4.34 M
Net Income -30.9 M
200m200m150m150m100m100m50m50m00(50m)(50m)167m(35m)132m(167m)(35m)4m(31m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.03% GROSS MARGIN
79.03%
-21.08% OPERATING MARGIN
-21.08%
-18.49% NET MARGIN
-18.49%
-18.51% ROE
-18.51%
-13.41% ROA
-13.41%
-17.24% ROIC
-17.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis SI-BONE, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -30.9 M
Depreciation & Amortization -1.06 M
Capital Expenditures -10.5 M
Stock-Based Compensation 25.9 M
Change in Working Capital -10.1 M
Others -1.64 M
Free Cash Flow -22.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets SI-BONE, Inc.
image
Wall Street analysts predict an average 1-year price target for SIBN of $21.3 , with forecasts ranging from a low of $18 to a high of $32 .
SIBN Lowest Price Target Wall Street Target
18 USD 9.82%
SIBN Average Price Target Wall Street Target
21.3 USD 29.87%
SIBN Highest Price Target Wall Street Target
32 USD 95.24%
Price
Max Price Target
Min Price Target
Average Price Target
32323030282826262424222220201818161614141212Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership SI-BONE, Inc.
image
Sold
0-3 MONTHS
2.16 M USD 5
3-6 MONTHS
1.44 M USD 5
6-9 MONTHS
359 K USD 4
9-12 MONTHS
402 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SI-BONE to Truist Securities MedTech Conference on June 17, 2025 SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. globenewswire.com - 1 month ago
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025 SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. globenewswire.com - 1 month ago
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025 SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time. globenewswire.com - 1 month ago
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 month ago
4 Recent Earnings Winners Riding Fresh Momentum in May The market turbulence in 2025 has sent stocks zig-zagging up and down. Despite the unavoidable impact of political developments on share price performance, some companies have seen major gains based on a more traditional driver of motion: strong earnings reports. marketbeat.com - 1 month ago
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now? Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 1 month ago
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025 SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. globenewswire.com - 1 month ago
SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Saqib Iqbal - VP, FP&A, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America David Turkaly - Citizens JMP Young Li - Jefferies Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Operator Good afternoon. And welcome to SI-BONE's First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. zacks.com - 1 month ago
SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9% U.S. revenue of $44.8 million, representing growth of 26.6% Gross margin of 79.7%, representing an improvement of 80 basis points Net loss of $6.5 million, representing an improvement of 40.0% Positive adjusted EBITDA of $0.5 million $144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective October 1, 2025, paying an additional amount up to $3,960 for procedures involving iFuse TORQ TNT SANTA CLARA, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript seekingalpha.com - 4 months ago
8. Profile Summary

SI-BONE, Inc. SIBN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 698 M
Dividend Yield 0.00%
Description SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Contact 471 El Camino Real, Santa Clara, CA, 95050 https://si-bone.com
IPO Date Oct. 17, 2018
Employees 349
Officers Ms. Laura A. Francis MBA Chief Executive Officer & Director Mr. Anshul Maheshwari Chief Financial Officer Mr. Jeffrey W. Dunn Executive Chairman Saqib Iqbal Director of FP&A and Investor Relations Mr. Nikolas F. Kerr Senior Vice President of Product, Marketing & Business Development Mr. Michael A. Pisetsky J.D. Chief Business & Legal Affairs Officer, Secretary and General Counsel Ms. Aimee Einstein Vice President of People & Culture Mr. Anthony J. Recupero President of Commercial Operations Dr. Scott A. Yerby Ph.D. Senior Vice President of Engineering & Chief Technology Officer Dr. Daniel Joseph Cher M.D. Senior Vice President of Clinical & Regulatory Affairs